Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Sirion Therapeutics (drug rights)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

United States rights for DUREZOL and emulsion and global rights for ZYCLORIN. DUREZOL emulsion is a topical ophthalmic corticosteroid used to treat postoperative inflammation and pain associated with ocular surgery. ZYCLORIN is a topical ophthalmic immunomodulator and immunosuppressive agent.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Business Products and Services
Acquirer
Primary Office
  • 3110 Cherry Palm Drive
  • Suite 340
  • Tampa, FL 33619
  • United States

Sirion Therapeutics (drug rights) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Sirion Therapeutics (drug rights)‘s full profile, request access.

Request full access to PitchBook

Sirion Therapeutics (drug rights) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Sirion Therapeutics (drug rights)‘s full profile, request access.

Request full access to PitchBook